| Malignant neoplasm of breast
Talzenna vs Herceptin Hylecta
Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of breast.Deep comparison between: Talzenna vs Herceptin Hylecta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsHerceptin Hylecta has a higher rate of injection site reactions vs Talzenna based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Herceptin Hylecta but not Talzenna, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Talzenna
Herceptin Hylecta
At A Glance
Oral
Daily
PARP inhibitor
SC injection
Every 3 weeks
HER2 antagonist
Indications
- Malignant neoplasm of breast
- Hormone refractory prostate cancer
- Malignant neoplasm of breast
Dosing
Malignant neoplasm of breast 1 mg orally once daily until disease progression or unacceptable toxicity.
Hormone refractory prostate cancer 0.5 mg orally once daily with enzalutamide until disease progression or unacceptable toxicity; patients should also receive a GnRH analog concurrently or have had bilateral orchiectomy.
Malignant neoplasm of breast 600 mg/10,000 units administered subcutaneously over approximately 2-5 minutes once every three weeks; no loading dose required; adjuvant patients treated for 52 weeks or until disease recurrence, metastatic patients treated until disease progression.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Fatigue, nausea, vomiting, diarrhea, headache, alopecia, decreased appetite, hemoglobin decreased, neutrophils decreased, lymphocytes decreased, platelets decreased
Serious Anemia, pyrexia
Most common (>=10%) Alopecia, nausea, administration-related reactions, neutropenia, diarrhea, asthenia, fatigue, vomiting, myalgia, decreased appetite, stomatitis, arthralgia, headache, rash, constipation, pyrexia, cough, anemia, dyspnea, peripheral sensory neuropathy, leukopenia, mucosal inflammation, hot flush, upper respiratory tract infection
Serious Neutropenia (Grade >=3), febrile neutropenia, leukopenia, left ventricular dysfunction, cardiomyopathy, pulmonary toxicity, hypersensitivity reactions
Postmarketing Administration-related reaction, oligohydramnios, glomerulopathy, immune thrombocytopenia, tumor lysis syndrome
Pharmacology
Talazoparib is an inhibitor of PARP enzymes (PARP1 and PARP2) involved in DNA repair; it induces cytotoxicity in cancer cells with DNA repair gene defects through inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, resulting in DNA damage, decreased cell proliferation, and apoptosis.
Trastuzumab is a humanized IgG1 kappa monoclonal antibody that inhibits proliferation of HER2-overexpressing tumor cells and mediates antibody-dependent cellular cytotoxicity (ADCC); hyaluronidase reversibly increases subcutaneous tissue permeability by depolymerizing hyaluronan to enhance systemic absorption of trastuzumab.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Talzenna
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
Herceptin Hylecta
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Talzenna
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (4/8)
Herceptin Hylecta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Talzenna
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Herceptin Hylecta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Talzenna.
Cost estimate not availableCancerCare: Bone Metastases
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TalzennaView full Talzenna profile
Herceptin HylectaView full Herceptin Hylecta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.